Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US - Clinical Drug Investigation
Source : https://link.springer.com/article/10.1007/s40261-022-01215-w
Background Gene therapy is known to be unaffordable to those who need it the most; however, evidence on the financial impact is limited. Objective This study aimed to estimate the...
Conclusions: This study suggests that the high cost of the gene therapy idecabtagene vicleucel is justifiable due to the low number of rrMM patients.
phase II clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
Brief Report | Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill,...
Conclusions: This is the first prospective clinical trial to demonstrate that combined BRAF/MEK inhibition is highly effective in patients with BRAFV600E mutated RRMM and represents a successful targeted precision medicine approach in this disease.
Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
Source : https://www.frontiersin.org/articles/10.3389/fimmu.2022.1079181/full
Chimeric antigen receptor T (CAR-T) cells technology has been successfully used in the treatment of B cell-derived hematological tumors and multiple myeloma. CAR-T cells are also being studied in a...
Conclusions: In this review, we summarized the serious adverse events of CAR-T cells in the treatment of malignant tumors by reading literature and searching relevant clinical studies, and discussed the management and treatment of serious adverse events in an effort to provide theoretical support for clinicians who deal with such patients.
The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers | CEOR
Multiple myeloma (MM) is a malignant clonal plasma cell proliferative disorder characterized by uncontrolled and progressive increase of monoclonal paraprotein leading to specific end-organ damage. The proliferating multiple myeloma cells...
Conclusions: NDMM is burdensome for patients and caregivers in the first year after diagnosis. TNE patients are more dependent on caregivers and incur higher care costs than TE patients. Despite the financial, physical, and emotional burden, HRQoL remains stable possibly indicating resilience and illness adjustment amongst patients and...
Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36411210/
Data collected to date support CAR-T therapies holding substantial promise for patients with heavily pretreated RRMM relative to other currently available therapies. Additional real-world data will help provide further insights...
Conclusions: Data collected to date support CAR-T therapies holding substantial promise for patients with heavily pretreated RRMM relative to other currently available therapies. Additional real-world data will help provide further insights into the comparative efficacy and safety profiles of these treatments in RRMM as these treatments become...